---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310472"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:02:21.169825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# ORIC presents enozertinib Phase 1b update; no specific results in filing

## Summary
- Company announced enozertinib (ORIC-114) program update on December 6, 2025.
- Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.
- No efficacy or safety figures included in the filing text itself.
- Investors must refer to the separate presentation for detailed data.

## SEC filing metadata
- accession: 0001193125-25-310472
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/0001193125-25-310472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/d46273d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310472
- JSON: https://secwatch.observer/filing/0001193125-25-310472.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310472.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.